Corvus Pharmaceuticals, Inc.

Contributing Author

Recent Articles by Corvus Pharmaceuticals, Inc.

Nov-04	Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results CRVS GlobeNewswire
Nov-03	Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting & Exposition CRVS GlobeNewswire
Oct-31	Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference CRVS GlobeNewswire
Oct-28	Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025 CRVS GlobeNewswire
Oct-17	Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025 CRVS GlobeNewswire
Oct-02	Corvus Pharmaceuticals Appoints David Moore to Board of Directors CRVS GlobeNewswire
Aug-07	Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results CRVS GlobeNewswire
Jul-31	Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2025 Financial Results on August 7, 2025 CRVS GlobeNewswire
Jun-25	Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis CRVS GlobeNewswire
Jun-11	Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress CRVS GlobeNewswire
Jun-04	Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis CRVS GlobeNewswire
May-28	Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference CRVS GlobeNewswire
May-08	Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results CRVS GlobeNewswire
May-08	Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis CRVS GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.